Gainesville, FL – December 16, 2024 – Evren Technologies, Inc., developer of a breakthrough neuromodulation treatment for PTSD, proudly announces that Dr. John Abernethy, MD, has joined its Scientific Advisory Board. With extensive expertise in behavioral health and addiction medicine, Dr. Abernethy brings a wealth of clinical insight to support Evren’s mission to transform the treatment of PTSD and related stress disorders.
Dr. Abernethy currently serves as Chief Medical Officer at Serodopa Therapeutics and Medical Director at Meridian Behavioral Healthcare, where he oversees a range of programs, including opioid treatment, detox units, and long-term residential care. He has worked extensively with patients seeking relief from PTSD, anxiety, and addiction, providing him with a profound understanding of the challenges faced by these populations. His experience aligns seamlessly with Evren’s mission to provide innovative, noninvasive vagus nerve stimulation (VNS) treatments for PTSD and other stress-related conditions.
In addition to his clinical work, Dr. Abernethy is a Major in the U.S. Army Reserve Medical Corps, where he has witnessed firsthand the devastating impact of PTSD on military personnel. His unique perspective will guide Evren’s efforts to address the needs of service members and veterans with targeted, evidence-based neuromodulation therapies.
“Dr. Abernethy’s clinical expertise and deep understanding of behavioral health and PTSD make him an invaluable addition to our Scientific Advisory Board,” said Rick Giancola, President and CEO of Evren Technologies. “His experience working directly with patients and his dedication to improving mental health care align perfectly with our mission to transform the treatment of PTSD and stress-related conditions through innovative neuromodulation therapies. We are excited to have him on board as we prepare to bring the Phoenix® device to those who need it most.”
Dr. Abernethy’s appointment comes at a pivotal moment for Evren Technologies, as the company advances the development of its flagship product, the Phoenix®. The Phoenix is a noninvasive vagus nerve stimulation research device designed to alleviate symptoms of PTSD, anxiety, and related conditions. With Dr. Abernethy’s guidance, Evren aims to refine its clinical protocols and ensure the Phoenix meets the needs of diverse patient populations.
“I am honored to join Evren Technologies' Scientific Advisory Board,” said Dr. Abernethy. “The innovative work they are doing in neuromodulation has the potential to make a profound difference in the lives of individuals suffering from PTSD and stress-related disorders. I am excited to bring my clinical experience to this dynamic team and contribute to advancing their groundbreaking mission.”
Evren Technologies is supported by a world-class Scientific Advisory Board and Board of Directors, including leading experts in mental health, neuroscience, and regulatory strategy. Dr. Abernethy’s expertise in behavioral health and addiction medicine further strengthens the company’s ability to deliver transformative solutions for mental health care.
About Evren Technologies
Evren is a bioelectronic medical device company in the field of neuromodulation devices and is transforming the treatment of PTSD, Acute Stress Reactions, Acute Stress Disorder, and Adjustment Disorders by delivering noninvasive, breakthrough, Vagal Nerve Stimulation (VNS) to the auricular branch of the vagus nerve. Our initial product -- the Phoenix® CR – administers transcutaneous auricular VNS (taVNS) safely and effectively in laboratory, clinical, and unsupervised home settings for VNS research use and was launched in late 2023. The Phoenix CR will also be the clinical trial device in Evren’s pivotal trial seeking De Novo classification from the FDA. It will deliver safe and effective taVNS therapy, with no known adverse side effects. Bioelectronic medicine uses sophisticated technology to modulate the electrical activity of the body’s nervous system and has the potential to supplement or even replace drugs or other interventions. Evren’s technology is based on stimulating the vagus nerve, the main nerve of the parasympathetic (“calming or safety”) branch of the autonomic nervous system. For further information about the Phoenix CR or Evren Technologies, please visit evrenvns.com.
CONTACT:
Josh Kelly, Director of Operations
Evren Technologies, Inc.
904.517.2432
Commenti